Aligos Therapeutics, Inc. (ALGS) Stock

Aligos Therapeutics, Inc. (ALGS) is a Healthcare stock trading at $6.63 (as of 2026-08-21), with a market capitalization of $41.03M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for viral and liver diseases, including chronic hepatitis B. Its pipeline includes ALG-010133 and ALG-000184, along with additional hepatitis B–targeting candidates and programs in non-alcoholic steatohepatitis and other approaches.

Understand Aligos Therapeutics, Inc.: how it makes money

Aligos Therapeutics develops novel biopharmaceutical therapeutics for viral and liver diseases, including chronic hepatitis B, using clinical-stage candidates such as ALG-010133 and ALG-000184, and it generates revenue categories that are reported as Revenue from Collaboration, Revenue from Customers, and Revenue from Custom Transactions (all shown as 0.0 in the latest quarter provided).

With lead drug candidates in Phase Ib and Phase I and the latest quarter showing 0.0 revenue across Revenue from Collaboration, Revenue from Customers, and Revenue from Custom Transactions, the company's near-term profit model depends on whether clinical progress translates into non-zero collaboration or customer related revenue.

Revenue by segment (latest quarter)
Collab	$0.0B
Customers	$0.0B
CustomTx	$0.0B

Business quality (Weak): Early-stage clinical development with limited disclosed operating traction in the provided quarter (revenue categories all at 0.0), and the key measurable datapoints in these facts are cohort enrollment and interim analysis milestones in chronic hepatitis B studies.

Bull case

Multiple chronic hepatitis B programs in clinical development: The company is advancing ALG-010133 (Phase Ib) and ALG-000184 (Phase I) to treat chronic hepatitis B, and it also develops additional hepatitis B focused candidates including ALG-020572 to prevent HBsAg translation and secretion.
Measurable trial progress signals are tracked: The provided operating KPIs include cohort enrollment and an interim milestone for HBeAg-minus participants reaching Week 12 or later, which can help investors gauge clinical progression over time.

Bear case

No revenue in the latest quarter provided: For the period ending 2026-03-31, Revenue from Collaboration, Revenue from Customers, and Revenue from Custom Transactions are all shown as 0.0 in these facts, limiting near-term funding visibility from operations.
High operating losses in the latest quarter provided: The operating margin for 2026-03-31 is -951.6 (gross margin is not provided here), indicating substantial operating loss pressure.
Clinical trial outcome risk: All cited lead assets are in Phase Ib or Phase I, so outcomes depend on clinical results, enrollment progress, and whether interim and later data support continued development.

Valuation — source: SEC EDGAR (first-party)
Price	$6.63
Market Cap	$41.03M
Price / Book	1.29
Price / Sales	6.41

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.19M
Net Margin	-1106.7%
Revenue Growth (YoY)	-39.5%
EPS Growth (YoY)	-88.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-11.87 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Deep Track Capital, LP ($3.30M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Lawrence Blatt
Employees	70
Country	US
IPO Date	2020-10-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.